Despite long (post-bone metastatic) OS of patients with EGFR-mutated NSCLC, and the high incidence of bone metastases in this patient population, occurrence of SRE and outcome of bone metastases is barely reported in clinical trials. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.